Page last updated: 2024-08-17

aspartic acid and Cancer of Pancreas

aspartic acid has been researched along with Cancer of Pancreas in 26 studies

Research

Studies (26)

Timeframe	Studies, this research(%)	All Research%
pre-1990	3 (11.54)	18.7374
1990's	7 (26.92)	18.2507
2000's	5 (19.23)	29.6817
2010's	9 (34.62)	24.3611
2020's	2 (7.69)	2.80

Authors

Authors	Studies
Alwaseem, H; Badgley, MA; Bar-Sagi, D; Baudrier, L; Birsoy, K; de Stanchina, E; Garcia-Bermudez, J; Hwang, RF; La, K; Liu, Y; Molina, H; Prasad, S; Rostandy, B; Soula, M; Taylor, LJ; Williams, RT; Yamaguchi, N	1
Abrego, J; Betts, CB; Bhattacharyya, S; Coussens, LM; Diaz, L; Nagarajan, S; Oon, C; Sandborg, H; Sanford-Crane, H; Sherman, MH; Sun, D; Tontonoz, P; Xia, Z; Xiao, X	1
Abrego, J; Chaika, NV; Gebregiworgis, T; Gunda, V; Mulder, SE; Powers, R; Purohit, V; Shukla, SK; Singh, PK; Tadros, S	1
Chen, C; Fei, K; Guo, L; Ju, R; Li, J; Li, S; Ye, C; Zhang, D; Zhu, L	1
Cole, G; Gabrail, NY; James, D; Khorana, AA; Ramanathan, RK; Shah, S; Thomas, GW; Wong, S; Zhou, C	1
Abt, ER; Armstrong, WR; Cabebe, AE; Capri, JR; Dann, AM; Donahue, TR; Elliott, IA; Ghukasyan, R; Kim, SS; Kim, W; Le, TM; Li, L; Matsumura, C; Moore, A; Poddar, S; Radu, CG; Tucker, DA; Williams, JL; Wu, N; Xu, S; Zhou, L	1
Guan, KL; Lin, H; Ling, ZQ; Shi, Q; Xiong, Y; Yang, H; Yang, Y; Ye, D; Zhang, M; Zhao, S; Zhao, Y; Zhou, L	1
Du, ZX; Gao, YY; Liu, BQ; Meng, X; Niu, XF; Wang, HQ; Zhang, HY	1
Bell, KM; Chung, CH; Gu, G; Means, AL; Ray, KC; Washington, MK; Yan, J	1
Batra, SK; Chakraborty, S; Jain, M; Kumar, S; Ponnusamy, MP; Rachagani, S; Senapati, S; Smith, LM	1
Fei, S; Ji, Y; Rao, S; Wang, H; Yao, X; Zeng, M	1
Bissonnette, RP; Colston, KW; Dalgleish, AG; Pettersson, F	1
Abbruzzese, JL; Ardalan, B; Balcerzak, SP; Benedetti, JK; Goodwin, JW; Lenz, HJ; Macdonald, JS; Samlowski, WE; Whitehead, RP	1
Abbruzzese, JL; Bondy, ML; Evans, DB; Hassan, MM; Jiao, L; Li, D	1
Dermadi Bebek, D; Greenblatt, M; Nyström, M; Ollila, S	1
Chabner, BA; Donehower, RC; Erlichman, C; Klecker, R; Speyer, JL	1
Ervin, TJ; Kufe, DW; Meshad, MW; Weiss, GR	1
Green, F; Hoffman, JP; O'Dwyer, PJ; Redei, I; Scher, R; Weiner, LM	1
Ardalan, B; Donofrio, K; Livingstone, AS; Markoe, A; Reddy, R; Richman, SP; Schwade, J; Ucar, A	1
Bakker, A; Finkelstein, SD; Keller, G; Pricolo, VE; Przygodzki, R; Sayegh, R; Swalsky, PA	1
Berns, T; Harstrick, A; Hiddemann, W; Köhne, CH; Preusser, P; Schmoll, HJ; Seeber, S; Strumberg, D; Wilke, H	1
Chidambaram, A; Fraser, MC; Goldstein, AM; Struewing, JP; Tucker, MA	1
Banerjee, TK; DiFino, SM; Engstrom, PF; Flynn, PJ; Heim, WJ; O'Dwyer, PJ; Ozols, RF; Rosvold, E; Schilder, R; Walczak, J	1
Bach, A; Fleming, TR; Goodman, P; MacDonald, JS; Morrell, LM; Richman, SP	1
Abe, M; Motoshima, K; Nagata, Y; Nakayama, E; Shiku, H	1
Ardalan, B; Silberman, H; Singh, G	1

Trials

7 trial(s) available for aspartic acid and Cancer of Pancreas

Article	Year
A Phase 2 Study of PCI-27483, a Factor VIIa Inhibitor in Combination with Gemcitabine for Advanced Pancreatic Cancer. Oncology, 2019, Volume: 96, Issue:4 Topics: Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Benzimidazoles; Blood Coagulation; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Monitoring; Factor VIIa; Female; Gemcitabine; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Pancreatic Neoplasms; Progression-Free Survival; Time Factors	2019
A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study. Investigational new drugs, 2004, Volume: 22, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Phosphonoacetic Acid; Pilot Projects; Prospective Studies; Survival Rate; Treatment Outcome	2004
Phase II trial of PALA and 6-methylmercaptopurine riboside (MMPR) in combination with 5-fluorouracil in advanced pancreatic cancer. Investigational new drugs, 1994, Volume: 12, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltransferase; Aspartic Acid; Female; Fluorouracil; Humans; Male; Methylthioinosine; Middle Aged; Pancreatic Neoplasms; Phosphonoacetic Acid	1994
Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas. Cancer, 1994, Oct-01, Volume: 74, Issue:7 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Combined Modality Therapy; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phosphonoacetic Acid; Radiotherapy Dosage	1994
Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer. Cancer chemotherapy and pharmacology, 1992, Volume: 29, Issue:4 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Drug Evaluation; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Pancreatic Neoplasms; Phosphonoacetic Acid; Survival Analysis	1992
A phase II multi-institutional trial of low-dose N-(phosphonacetyl)-L-aspartate and high-dose 5-fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas. A Southwest Oncology Group study. Cancer, 1991, Jan-15, Volume: 67, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Drug Administration Schedule; Drug Evaluation; Drug Synergism; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phosphonoacetic Acid; Survival Rate	1991
A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1988, Volume: 6, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Humans; Male; Middle Aged; Organophosphorus Compounds; Pancreatic Neoplasms; Phosphonoacetic Acid; Random Allocation; Rectal Neoplasms	1988

Other Studies

19 other study(ies) available for aspartic acid and Cancer of Pancreas

Article	Year
Adaptive stimulation of macropinocytosis overcomes aspartate limitation in cancer cells under hypoxia. Nature metabolism, 2022, Volume: 4, Issue:6 Topics: Aspartic Acid; Cell Line, Tumor; Humans; Hypoxia; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras)	2022
A Cancer Cell-Intrinsic GOT2-PPARδ Axis Suppresses Antitumor Immunity. Cancer discovery, 2022, 10-05, Volume: 12, Issue:10 Topics: Aspartate Aminotransferases; Aspartic Acid; Carcinoma, Pancreatic Ductal; Fatty Acids; Humans; Ligands; Malates; Pancreatic Neoplasms; PPAR delta; Tumor Microenvironment	2022
Glucose Limitation Alters Glutamine Metabolism in MUC1-Overexpressing Pancreatic Cancer Cells. Journal of proteome research, 2017, 10-06, Volume: 16, Issue:10 Topics: Aspartic Acid; Cell Line, Tumor; Cell Proliferation; Citric Acid Cycle; DNA Replication; Glucose; Glutamine; Glycolysis; Humans; Magnetic Resonance Spectroscopy; Metabolomics; Mucin-1; Oxaloacetic Acid; Pancreatic Neoplasms	2017
Metabolic Mechanisms and a Rational Combinational Application of Carboxyamidotriazole in Fighting Pancreatic Cancer Progression after Chemotherapy. The Journal of pharmacology and experimental therapeutics, 2018, Volume: 367, Issue:1 Topics: Animals; Antineoplastic Agents; Aspartic Acid; Cell Line, Tumor; Cell Proliferation; Cell Respiration; Deoxyglucose; Disease Progression; Drug Interactions; Female; Glycolysis; Humans; Intracellular Space; Mice; Mice, Inbred BALB C; Mitochondria; Pancreatic Neoplasms; Triazoles; Xenograft Model Antitumor Assays	2018
Lysosome inhibition sensitizes pancreatic cancer to replication stress by aspartate depletion. Proceedings of the National Academy of Sciences of the United States of America, 2019, 04-02, Volume: 116, Issue:14 Topics: Animals; Aspartic Acid; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Chloroquine; Female; Humans; Lysosomes; Male; Mice; Mitochondria; Pancreatic Neoplasms; Stress, Physiological; Xenograft Model Antitumor Assays	2019
SIRT3-dependent GOT2 acetylation status affects the malate-aspartate NADH shuttle activity and pancreatic tumor growth. The EMBO journal, 2015, Apr-15, Volume: 34, Issue:8 Topics: Acetylation; Animals; Aspartate Aminotransferase, Mitochondrial; Aspartic Acid; Biological Transport; Carcinoma, Pancreatic Ductal; Cell Proliferation; Cells, Cultured; HEK293 Cells; Humans; Malates; Male; Mice; Mice, Inbred C57BL; Mice, Nude; NAD; Oxidation-Reduction; Pancreatic Neoplasms; Protein Processing, Post-Translational; Sirtuin 3	2015
Characterization of BAG3 cleavage during apoptosis of pancreatic cancer cells. Journal of cellular physiology, 2010, Volume: 224, Issue:1 Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Apoptosis Regulatory Proteins; Aspartic Acid; Caspase Inhibitors; Caspases; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Etoposide; Humans; Leupeptins; Mutation; Pancreatic Neoplasms; Peptide Fragments; Protein Processing, Post-Translational; Protein Structure, Tertiary; Recombinant Proteins; Staurosporine; Time Factors; Transfection; Tumor Necrosis Factor-alpha; Ultraviolet Rays	2010
Epithelial tissues have varying degrees of susceptibility to Kras(G12D)-initiated tumorigenesis in a mouse model. PloS one, 2011, Feb-02, Volume: 6, Issue:2 Topics: Amino Acid Substitution; Animals; Aspartic Acid; Carcinoma in Situ; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Disease Models, Animal; Disease Susceptibility; Epithelium; Glycine; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mouth Neoplasms; Mutation, Missense; Pancreatic Neoplasms; Papilloma; Proto-Oncogene Proteins p21(ras)	2011
Activated KrasG¹²D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin. British journal of cancer, 2011, Mar-15, Volume: 104, Issue:6 Topics: Adenocarcinoma; Amino Acid Substitution; Animals; Aspartic Acid; Cadherins; Down-Regulation; Gene Expression Regulation, Neoplastic; Glycine; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Point Mutation; Proto-Oncogene Mas; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; RNA, Small Interfering; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2011
Metabolite detection of pancreatic carcinoma by in vivo proton MR spectroscopy at 3T: initial results. La Radiologia medica, 2012, Volume: 117, Issue:5 Topics: Adult; Aged; Aspartic Acid; Biomarkers, Tumor; Choline; Dipeptides; Fatty Acids, Unsaturated; Female; Glutamic Acid; Glutamine; Humans; Magnetic Resonance Spectroscopy; Male; Middle Aged; Pancreatic Neoplasms; Software	2012
Retinoids cause apoptosis in pancreatic cancer cells via activation of RAR-gamma and altered expression of Bcl-2/Bax. British journal of cancer, 2002, Aug-27, Volume: 87, Issue:5 Topics: Adenocarcinoma; Alitretinoin; Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Aspartic Acid; bcl-2-Associated X Protein; Cysteine Proteinase Inhibitors; DNA Fragmentation; Drug Resistance; Fatty Acids, Unsaturated; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Mice; Mitochondria; Neoplasm Proteins; Pancreatic Neoplasms; Protein Isoforms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Receptors, Retinoic Acid; Recombinant Fusion Proteins; Retinoic Acid Receptor gamma; Retinoid X Receptors; Retinoids; Transcription Factors; Transfection; Tretinoin; Tumor Cells, Cultured	2002
The XPD Asp312Asn and Lys751Gln polymorphisms, corresponding haplotype, and pancreatic cancer risk. Cancer letters, 2007, Jan-08, Volume: 245, Issue:1-2 Topics: Adenocarcinoma; Aged; Amino Acid Substitution; Asparagine; Aspartic Acid; Carcinoma, Pancreatic Ductal; Case-Control Studies; Female; Gene Frequency; Genotype; Glutamine; Haplotypes; Humans; Linkage Disequilibrium; Lysine; Male; Middle Aged; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Risk Factors; Smoking; Xeroderma Pigmentosum Group D Protein	2007
Uncertain pathogenicity of MSH2 variants N127S and G322D challenges their classification. International journal of cancer, 2008, Aug-01, Volume: 123, Issue:3 Topics: Asparagine; Aspartic Acid; Biliary Tract Neoplasms; Blotting, Western; Colorectal Neoplasms, Hereditary Nonpolyposis; DNA Mismatch Repair; DNA-Binding Proteins; Endometrial Neoplasms; Female; Genetic Predisposition to Disease; Germ-Line Mutation; Glycine; Humans; Immunoprecipitation; MutS Homolog 2 Protein; Pancreatic Neoplasms; Serine; Uncertainty	2008
Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection. Journal of the National Cancer Institute, 1982, Volume: 68, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouracil; Humans; Infusions, Parenteral; Male; Melanoma; Middle Aged; Neoplasms; Organophosphorus Compounds; Ovarian Neoplasms; Pancreatic Neoplasms; Phosphonoacetic Acid; Sarcoma	1982
Phase II trial of combination therapy with continuous-infusion PALA and bolus-injection 5-FU. Cancer treatment reports, 1982, Volume: 66, Issue:2 Topics: Adult; Aged; Aspartic Acid; Breast Neoplasms; Carcinoma; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combination; Fluorouracil; Humans; Infusions, Parenteral; Injections, Intravenous; Middle Aged; Organophosphorus Compounds; Pancreatic Neoplasms; Phosphonoacetic Acid; Sarcoma	1982
K-ras-2 topographic genotyping of pancreatic adenocarcinoma. Archives of surgery (Chicago, Ill. : 1960), 1994, Volume: 129, Issue:4 Topics: Adenocarcinoma; Alanine; Arginine; Aspartic Acid; Codon; Cysteine; DNA, Neoplasm; Exons; Forecasting; Genes, ras; Genotype; Glycine; Humans; Leucine; Mutation; Pancreas; Pancreatic Neoplasms; Serine; Survival Rate; Valine	1994
Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:9 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Female; Fluorouracil; Humans; Male; Methotrexate; Middle Aged; Pancreatic Neoplasms; Phosphonoacetic Acid	1997
Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. Journal of the National Cancer Institute, 2000, Jun-21, Volume: 92, Issue:12 Topics: Adolescent; Adult; Age Factors; Aged; Arginine; Aspartic Acid; Cyclin-Dependent Kinases; Cysteine; Genes, p16; Genotype; Germ-Line Mutation; Glycine; Haplotypes; Humans; Melanoma; Middle Aged; Nevus; Pancreatic Neoplasms; Phenotype; Skin Neoplasms; Statistics, Nonparametric; Tryptophan; United States; Valine	2000
Frequent glycine-to-aspartic acid mutations at codon 12 of c-Ki-ras gene in human pancreatic cancer in Japanese. Japanese journal of cancer research : Gann, 1990, Volume: 81, Issue:2 Topics: Adult; Aged; Asian People; Aspartic Acid; Codon; Female; Genes, ras; Glycine; Humans; Japan; Male; Middle Aged; Mutation; Pancreatic Neoplasms; RNA, Messenger; Smoking	1990